How Do We Get CAC Below LTV Sustainably in Healthtech / Digital Health?
Direct answer: In healthtech, a sustainable CAC-to-LTV relationship depends on the retention and reimbursement mechanics behind your revenue, not just your paid-acquisition efficiency. You reach it by measuring contribution-margin LTV (not gross revenue), segmenting economics by payer type and acquisition channel, and confirming that your CAC payback period is shorter than your realistic member or provider retention window. Most digital health companies discover their problem is churn and margin — not top-of-funnel cost — once they run the math honestly.
Why Unit Economics Breaks Differently in Healthtech
The generic SaaS rule — "keep LTV/CAC above 3x" — misleads healthtech founders because the industry has structural features that distort both sides of the ratio:
- Long, multi-stakeholder sales cycles. In B2B2C models, you acquire a payer or employer, but your revenue depends on downstream member enrollment and engagement. Your true CAC includes clinical validation, security reviews, and pilot periods that can run 6–18 months.
- Reimbursement complexity. Revenue per user varies by CPT codes, value-based contracts, PMPM fees, or cash-pay. Two members on the same product can have wildly different contribution margins.
- Regulatory and clinical delivery costs. Care delivery, licensed clinician time, HIPAA infrastructure, and pharmacy fulfillment eat into gross margin in ways pure software does not.
- Retention driven by outcomes, not habit. Members churn when they get healthy, lose coverage, or change employers — often outside your control.
So "get CAC below LTV" is the wrong framing. The right framing is: is contribution-margin LTV comfortably above fully-loaded CAC, within a payback window your balance sheet can survive?
Running the Unit Economics Framework: A Healthtech Walkthrough
Unit Economics is one of the 27+ frameworks we apply at Percision, where I work on content. Here's how to run it honestly on a digital health business.
Step 1 — Define the unit. Is it a member, a covered life, a provider seat, or an enrolled patient episode? Pick the unit that ties directly to revenue. In B2B2C, model both the contract (payer/employer) and the individual (member) — they have different economics.
Step 2 — Build contribution-margin LTV, not revenue LTV. Start with average revenue per unit, then subtract:
- Cost of clinical delivery (clinician time, care coordination)
- Fulfillment and pharmacy costs
- Payment processing and claims-adjudication costs
- Support and account-management cost per unit
What's left is contribution margin per period. Multiply by expected lifetime (1 / churn rate), then discount for time value if lifetimes are long.
Step 3 — Fully load CAC. Include the parts founders leave out: sales salaries, pilot and implementation costs, clinical validation studies, security/compliance reviews required to close, and the cost of failed pilots. In B2B2C, allocate blended CAC across the members who actually enroll — not the theoretical covered lives.
Step 4 — Calculate payback period. Fully-loaded CAC ÷ monthly contribution margin per unit. This is the number that determines whether growth burns or funds itself.
Step 5 — Segment everything. Run the model by channel, payer type, and cohort vintage. Aggregate ratios hide the truth: one enterprise channel may be wildly profitable while a paid-search consumer channel loses money on every acquisition.
What "good" looks like in healthtech:
- Contribution-margin LTV/CAC of 3x or higher, but confidence in the retention assumption matters more than the multiple.
- CAC payback under 12 months for consumer/cash-pay models; enterprise B2B2C can tolerate longer if contracts are multi-year and gross retention is strong.
- Gross retention (logo and revenue) that you can defend with cohort data, not projections.
- Contribution margin that improves as you scale — a sign your model isn't structurally negative.
If your payback exceeds your realistic retention window, you don't have a marketing problem. You have a business-model problem, and more ad spend makes it worse.
Where Percision Fits — and Where It Doesn't
Percision is an AI strategic-intelligence platform that runs your business context through structured reasoning steps to produce board-ready analysis in minutes rather than weeks. For unit economics, it's useful when you need to:
- Build a segmented LTV/CAC and payback model with an Excel-exportable audit trail you can defend to a board or diligence team.
- Pressure-test retention and margin assumptions across scenarios (what if churn rises 20%? what if a payer contract renews at lower PMPM?).
- Turn the diagnosis into an execution plan with KPI dashboards tracking payback and cohort retention over time.
- Produce a board deck quickly when you're mid-raise or mid-planning cycle.
It's positioned as a co-pilot, never an autopilot — your leadership team owns the assumptions and the decisions.
When you don't need Percision: If you're pre-revenue with one channel and 30 customers, a clean spreadsheet is enough — and you should build it yourself to internalize the drivers. If your economics hinge on a nuanced reimbursement or regulatory question, a healthcare-finance consultant or your reimbursement counsel will out-perform any general tool. And if you already have a strong FP&A team running cohort models monthly, use Percision to accelerate and benchmark, not replace them.
The honest test: use software when speed and structure help; use humans when judgment about payer behavior and clinical delivery is the bottleneck.
If you want to run a segmented unit-economics analysis and turn it into a tracked execution plan, you can try Percision here.
What this looks like when the analysis is actually run
By selling to customers who are already inside the building — 180 of them, attached to contracts that already exist.
The subject is Vantabridge Health, a sample company profile we use for testing rather than a customer: a virtual chronic-care platform, $62M revenue, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy (T2) · sample company profile
The acquisition cost being avoided. Because the 180 self-insured employers sit inside existing health-plan relationships, the 11-month sales cycle is bypassed; instead a 4–6 month upsell process is used.
What it costs to work that base. $0.6–0.9M total — 2 FTE employer specialists at $180K fully loaded each over 18 months, plus $120K of enablement tools — from the existing $48M runway.
What it returns. $3.9M of incremental employer outcomes revenue in Year 1, $11.7M cumulative by Month 24, $18.5M cumulative in Year 3 at 15% YoY cohort growth. A 13.0× return on $0.9M.
The lifetime side. Health-plan logo churn on the engine cohort at 6% or better against a current 9%; employer engagement at 45% or better against 41%; device-kit leakage from 59% to 35% of the enrolled base, against $6.5M of kit cost.
The stop. Employer conversion below 25% by Month 12; at-risk share demanded above 50%; or device-kit leakage reduction under 10 points by Month 18.
| Metric | Target | By |
|---|---|---|
| Employer outcomes revenue | $3.9M by Month 12, $11.7M by Month 24 | Month 24 |
| Employer engagement rate | ≥45% (vs current 41%) | Month 18 |
| Device-kit leakage on employer cohort | ≤35% (vs current 59%) | Month 18 |
| Blended at-risk share across employer book | 45% (vs 38% payer average) | Month 24 |
An 11-month sales cycle is the real CAC in this business — not the media spend but the eleven months of clinical, actuarial and procurement work before a contract signs. Cutting it to four to six months by selling inside an existing relationship changes the ratio more than any channel optimisation would.
The retention half is doing equal work. Churn at 6% against 9% on a $62M base is roughly $1.9M of revenue that does not have to be reacquired each year, which is the cheapest form of customer acquisition available.
Read a complete Percision report — every page, no email required.
FAQ
What LTV/CAC ratio should a digital health company target? 3x on a contribution-margin basis is a reasonable benchmark, but the ratio matters less than two things: how confident you are in the retention assumption behind LTV, and whether your CAC payback period fits inside your realistic member lifetime.
Should we count pilot and clinical-validation costs in CAC? Yes. Anything you spend to win and onboard a customer — including failed pilots, security reviews, and validation studies — belongs in fully-loaded CAC. Excluding them produces flattering, misleading ratios.
Our LTV/CAC looks great but we're still burning cash — why? Usually because the LTV uses gross revenue instead of contribution margin, assumes optimistic retention, or blends a profitable enterprise channel with a losing consumer one. Segment by cohort and channel, and recompute on contribution margin.
Disclosure: This article was written by Percision's content team. We aim to present the platform as one strong option among several, including spreadsheets and human consultants.